Skip to content Skip to footer
Subscribe Now
Insights + EMA Marketing Authorization of New Drugs in July 2024
INSIGHTS+

Insights+: EMA Marketing Authorization of New Drugs in July 2024

Shots:    The EMA granted Positive Opinion to 2 Biologics and 5 New Chemical Entities in July 2024, leading to treatments for patients and advances in the healthcare industry   The major highlighted drugs were Johnson & Johnson’s Yuvanci to treat Pulmonary Arterial Hypertension (PAH) and Astellas’ Vyloy + CT for Gastric & Gastroesophageal Junction Cancer   PharmaShots has compiled a list…
August 14, 2024

Read more

ThoughtSpot_Evans James9
THOUGHTSPOT

How Can ABA Practice Management Software Simplify Your Administrative Work?

ABA practice management software revolutionizes how therapy practices handle administrative tasks. By centralizing operations, these systems streamline workflows and automate time-consuming processes. Therapists can significantly reduce non-billable hours, freeing up valuable time to focus on delivering quality care to clients. Implementing this technology brings numerous benefits to ABA practices. It enhances efficiency by simplifying scheduling,…
August 12, 2024

Read more

Viewpoints_Jennifer Fernandez
VIEWPOINTS

TCOC Management in Oncology: Jennifer Fernandez from The Oncology Network in a Dialogue Exchange with PharmaShots

Shots:  Prominent oncology drugs like pembrolizumab and nivolumab were initially approved with weight-based dosing and gradually transitioned to fixed dozing. With the transformation in the dosing model, the average dose amount administered to patients increased dramatically in the Oncology Care Model  Today, at PharmaShots, we have Jennifer Fernandez from The Oncology Network, shedding light on…
August 7, 2024

Read more

ThoughtSpot_Saurabh Chaubey5
THOUGHTSPOT

How Innovative Public Relation Solutions Shape the Biopharma Industry?

Shots:   In the internet-driven world where social media shape opinions and perspectives, it is imperative for companies in the biopharma industry to leverage innovative PR solutions  PR solutions offer significant advantages for biopharma companies that help build their brand values, increase credibility amongst consumers and stakeholders, and much more  With hand-curated offerings designed especially for…
August 6, 2024

Read more

Viewpoints_Dr. Robert Rifikin
VIEWPOINTS

Establishing Safe Treatment: Dr. Robert Rifikin from Rocky Mountain Cancer Centers in Conversation with PharmaShots

Shots:  There is an average lifetime risk of getting multiple myeloma of about 1 in 103 men and 1 in 131 women in the United States  Treatment of multiple myeloma using fourth-line therapy like teclistamab can induce issues like cytokine release syndrome (CRS) and neurotoxicity   Today, at PharmaShots we have Dr. Robert Rifikin from Rocky…
August 5, 2024

Read more

Insights+ Key Biosimilars Events of July 2024
INSIGHTS+

Insights+ Key Biosimilars Events of July 2024

Shots:     Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency      Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients      The major highlights were the US FDA’s approval of Samsung Bioepis’ Epysqli for Treating Paroxysmal…
August 1, 2024

Read more

New Drug Designations - June 2024
INSIGHTS+

New Drug Designations – June 2024

Shots:   PharmaShots' designation report provides a concise overview of several drugs and their designations by the FDA, NMPA and EMA. This month’s report includes designations allotted to 7 small molecules, 5 biologics, 8 cell & gene therapies, 2 recombinant fusion protein, and 3 devices   This month, ChromaDex’s Nicotinamide Riboside Chloride received US FDA’s ODD &…
July 30, 2024

Read more

Viewpoints_Tahi Ahmadi
VIEWPOINTS

Enhancing Capabilities: Tahi Ahmadi from Genmab in a Riveting Dialogue Exchange with PharmaShots

Shots:  Recently, Genmab acquired ProfoundBio in a strategic move to strengthen its position in the ADC space. With this acquisition, Genmab gets ProfoundBio’s novel ADC technology platforms  Today, at PharmaShots, we have Tahi Ahmadi, EVP and Chief Medical Officer at Genmab, sharing insights from the recent acquisition of ProfoundBio by Genmab  With this acquisition, Genmab…
July 29, 2024

Read more

Load more